Migraine marketing wars? AbbVie, Biohaven, Eli Lilly, Amgen lead push for attention in newly competitive space
For a long time, migraine sufferers were stuck with the same old medicines and advice. Try some triptans, change your diet, maybe even see if a narcotic might help — but no major drug advances to prevent or stop debilitating migraine episodes in almost 30 years.
Fast forward to 2021. With seven new drug approvals in the past three years, the once-moribund migraine market is suddenly competitive. That’s good news for patients because the new meds from AbbVie, Biohaven, Eli Lilly, Amgen, Teva and Lundbeck offer a variety of delivery methods and fewer side effects.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,800+ biopharma pros reading Endpoints daily — and it's free.